Diabetes careSep 16, 2026

How India Makes New Diabetes Medicines Affordable and Available for Other Countries

GLP-1 Therapies Weekly Brief ↗PubMed ↗DOI ↗

Updated Sep 17, 2026

Abstract

India has achieved approximately 60%-90% price reductions for modern diabetes therapies following patent expiry.

Affordability of modern diabetes therapies remains a significant barrier, particularly in low- and middle-income countries.
Strong generic competition and structured price regulation have facilitated major cost reductions for sodium-glucose cotransporter 2 inhibitors and glucagon-like peptide 1 receptor agonists.
Insulin biosimilars in India are also much more affordable compared to prices in other countries.
Cross-national comparisons reveal 15- to 65-fold differences between Indian generic prices and U.S. list prices for selected diabetes medications.
Government initiatives, such as Ayushman Bharat, have increased accessibility for economically vulnerable populations.
Challenges persist in rural areas, where access to modern diabetes therapies may still be limited or unaffordable.

Simplified

Diabetes affects 589 million adults globally, 80% of whom live in low- and middle-income countries (LMICs). Although modern diabetes therapies such as sodium-glucose cotransporter 2 inhibitors (SGLT2i) and glucagon-like peptide 1 receptor agonists (GLP-1 RA) improve cardiovascular and renal outcomes and analog insulins help reduce risk of hypoglycemia, affordability remains a barrier to equitable access to these agents. This article analyzes how India has reduced the costs of modern diabetes therapies and improved affordability, pricing trends, regulatory frameworks, pharmaceutical manufacturing policies, and public distribution initiatives in India. India has achieved approximately 60%-90% price reductions for SGLT2i and GLP-1 RA following patent expiry, driven by strong generic competition, structured price regulation, and governmental support, leading to much greater access to these agents. Costs of insulin biosimilars of glargine are also much lower in India, making them more affordable. Cross-national price comparisons show 15- to 65-fold differences between Indian generic prices and U.S. list prices for selected agents. On the policy front, government initiatives like the Ayushman Bharat have considerably helped to increase accessibility for the poor and vulnerable sections of the society. Despite these advances, challenges remain, particularly in rural areas where modern therapies may still be unaffordable or unavailable. Moreover, due to multiple manufacturers providing generics, there could be differences in quality and pharmacokinetics, even between the branded generics. However, India's experience demonstrates that affordable access to modern diabetes medicines is achievable through coordinated pharmaceutical policy, regulatory efficiency, and enhanced manufacturing capacity, offering lessons for LMICs and high-income countries facing high drug costs.

Full Text

Full text is available at the source.

View Full Text ↗

How India Makes New Diabetes Medicines Affordable and Available for Other Countries

Abstract

Full Text

You found one interesting study. We’ll send the next 7.

What Lands in Your Inbox Each Week:

Recent issues from the glp-1 therapies brief